Abstract
The management of metastatic bladder cancer is palliative. Best outcomes are achieved in those who are fit enough for systemic therapies. The place of radiotherapy in these patients is mainly for symptom control, in particular haematuria. However, a small proportion, especially those with oligometastases, will benefit from more radical treatment. In this review, we look at the evidence currently available for radiotherapy in this setting.
Highlights
Bladder cancer is the ninth most common cancer in the world[1,2]
Longer survival was only significantly associated with metastasectomy in those with single brain metastasis (9 months, 95%CI: 6.1-11.9 vs. 2 months without resection, 95%CI: 1.1-2.9, P < 0.001)
Distant metastasis-directed therapy Cancer-specific and overall survival in patients with metastatic urothelial carcinoma depends on the sites of visceral involvement and the number of deposits
Summary
Bladder cancer is the ninth most common cancer in the world[1,2]. The main histological subtype is urothelial carcinoma. In one of the larger series of 62 bladder cancer patients with brain metastases, there was no survival benefit with surgery plus radiotherapy over radiotherapy alone[66].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
